Detalhe da pesquisa
1.
LRRK2 is a negative regulator of Mycobacterium tuberculosis phagosome maturation in macrophages.
EMBO J
; 37(12)2018 06 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-29789389
2.
Impact of Type II LRRK2 inhibitors on signaling and mitophagy.
Biochem J
; 478(19): 3555-3573, 2021 10 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-34515301
3.
5-Substituted-N-pyridazinylbenzamides as potent and selective LRRK2 inhibitors: Improved brain unbound fraction enables efficacy.
Bioorg Med Chem Lett
; 29(2): 212-215, 2019 01 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-30522952
4.
Discovery of 4-ethoxy-7H-pyrrolo[2,3-d]pyrimidin-2-amines as potent, selective and orally bioavailable LRRK2 inhibitors.
Bioorg Med Chem Lett
; 28(9): 1615-1620, 2018 05 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-29588215
5.
Discovery of 5-substituent-N-arylbenzamide derivatives as potent, selective and orally bioavailable LRRK2 inhibitors.
Bioorg Med Chem Lett
; 27(17): 4034-4038, 2017 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28774425
6.
Phos-tag analysis of Rab10 phosphorylation by LRRK2: a powerful assay for assessing kinase function and inhibitors.
Biochem J
; 473(17): 2671-85, 2016 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27474410
7.
Characterization of the cellular action of the MSK inhibitor SB-747651A.
Biochem J
; 441(1): 347-57, 2012 Jan 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-21970321
8.
GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor.
Bioorg Med Chem Lett
; 22(17): 5625-9, 2012 Sep 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-22863203
9.
Inhibition of LRRK2 kinase activity leads to dephosphorylation of Ser(910)/Ser(935), disruption of 14-3-3 binding and altered cytoplasmic localization.
Biochem J
; 430(3): 405-13, 2010 Sep 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-20659021
10.
Pharmacological rescue of impaired mitophagy in Parkinson's disease-related LRRK2 G2019S knock-in mice.
Elife
; 102021 08 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-34340748
11.
Substrate specificity and inhibitors of LRRK2, a protein kinase mutated in Parkinson's disease.
Biochem J
; 424(1): 47-60, 2009 Oct 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-19740074
12.
The identification of potent, selective and CNS penetrant furan-based inhibitors of B-Raf kinase.
Bioorg Med Chem Lett
; 18(15): 4373-6, 2008 Aug 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-18621524
13.
A kinase-dependent role for EphA2 receptor in promoting tumor growth and metastasis.
Oncogene
; 24(53): 7859-68, 2005 Nov 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-16103880
14.
A High-Throughput Screen to Identify LRRK2 Kinase Inhibitors for the Treatment of Parkinson's Disease Using RapidFire Mass Spectrometry.
J Biomol Screen
; 21(2): 145-55, 2016 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-26403521
15.
Phosphoproteomics reveals that Parkinson's disease kinase LRRK2 regulates a subset of Rab GTPases.
Elife
; 52016 Jan 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-26824392
16.
MSK1 and MSK2 inhibit lipopolysaccharide-induced prostaglandin production via an interleukin-10 feedback loop.
Mol Cell Biol
; 33(7): 1456-67, 2013 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-23382072
17.
FRAT1, a substrate-specific regulator of glycogen synthase kinase-3 activity, is a cellular substrate of protein kinase A.
J Biol Chem
; 281(46): 35021-9, 2006 Nov 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-16982607
18.
The identification of potent and selective imidazole-based inhibitors of B-Raf kinase.
Bioorg Med Chem Lett
; 16(2): 378-81, 2006 Jan 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-16260133
19.
Expression and characterization of GSK-3 mutants and their effect on beta-catenin phosphorylation in intact cells.
J Biol Chem
; 277(26): 23330-5, 2002 Jun 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-11967263
20.
Mitogen and stress response kinase-1 (MSK1) mediates excitotoxic induced death of hippocampal neurones.
J Neurochem
; 86(1): 25-32, 2003 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-12807421